AlncRNA HULC as an effective biomarker for surveillance of the outcome of cancer: A meta-analysis
Xiaoliang Chen
Jinbo Lin
Yi Liu
Ji Peng
Yong Cao
Zhan Su
Tieqiang Wang
Jinquan Cheng
Dongsheng Hu
10.1371/journal.pone.0171210
https://plos.figshare.com/articles/dataset/AlncRNA_HULC_as_an_effective_biomarker_for_surveillance_of_the_outcome_of_cancer_A_meta-analysis/4610029
<div><p>Purpose</p><p>High expression of highly upregulated in iver cancer (HULC) has been found associated with increased metastasis and poor prognosis with cancer. This meta-analysis aimed to determine the pooled effect of HULC on metastasis and prognosis of cancers.</p><p>Method</p><p>The studies were accessed using multiple databases. RevMan5.3 and STATA14.0 were used to estimate pooled effects, the heterogeneity among studies, and publication bias for the association of HULC and overall survival (OS).</p><p>Results</p><p>A total of 9 studies of 966 cancer patients were included. Risk of lymph node metastasis was increased with high versus low HULC expression (pooled odds ratio [OR] = 4.83, 95% confidence interval [CI] 1.59–14.63) as was distant metastasis (pooled OR = 5.44, 95% CI 2.33–12.74). Furthermore, OS time was shortened with high HULC expression (pooled hazard ratio [HR] = 1.48, 95% CI 1.03–2.12), especially in Chinese patients (pooled HR = 2.04, 95% CI 1.55–2.68), and risk of recurrence was increased (pooled OR = 6.68, 95% CI 2.77–16.13).</p><p>Conclusion</p><p>HULC might be a potential biomarker for therapy and prognosis surveillance in cancers.</p></div>
2017-02-01 17:30:02
HR
966 cancer patients
CI
prognosis
lymph node metastasis
HULC expression
STATA
OS
meta-analysis Purpose High expression